AMDL Receives U.S. Patent for its Immunogene Therapy for Cancer
May 25 2004 - 8:00AM
PR Newswire (US)
AMDL Receives U.S. Patent for its Immunogene Therapy for Cancer
TUSTIN, Calif., May 25 /PRNewswire-FirstCall/ -- AMDL, Inc. ,
developer and marketer of tests for the early detection of cancer
and other serious diseases, which recently announced it launched a
major effort to seek a strategic partner for clinical trials, and
eventual marketing, of its unique Combination Immunogene Therapy
(CIT), today said the technology has received a United States
Patent. CIT uses two genes in combination to build the body's
immune system and to destroy cancer cells. The GM-CSF gene alters
the tumor to activate tumor-specific T-cells within the immune
system, while the B7-2 gene enters the tumor to stimulate larger
and stronger T-cells to fight the cancer. This is a variation of
the traditional concept of gene therapy, which seeks to replace
damaged or abnormal genes with healthy ones. Replacing defective
genes in cancer cells has proven impractical because of the number
of genes involved. CIT has undergone successful Phase I clinical
trials in skin and brain cancer patients and was shown to be 100
percent effective in a humanized mouse model at the University of
Alberta, Canada. Publications that have reported on this therapy
include "Human Gene Therapy" and "Neurosurgery." "The search is on
to find potential treatments in the multi-billion dollar global
cancer market and we believe our therapy has significant, important
features to offer," said Gary Dreher, AMDL President and CEO. AMDL
is a theranostics company, meaning it is involved both in the
treatment of cancer, with the CIT therapy, and in its detection,
with the DR-70(R) cancer blood test kit. The Company currently is
supplying information requested by the U.S. Food and Drug
Administration as part of the process in seeking clearance to
market the DR-70(R) test. About AMDL AMDL, Inc. (AMEX:ADL),
headquartered in Tustin, California, is a theranostics company,
involved in the detection and treatment of the same disease,
cancer. AMDL is the inventor, developer and worldwide marketer
through exclusive distribution agreements of the DR-70(R)
non-invasive cancer blood test, which has demonstrated its ability
to detect the presence in humans of up to 13 cancers 84 percent of
the time overall. In a study published in the Journal of
Immunoassay (1998, vol. 19, pp 63-72) DR-70(R) was shown to detect
at least 13 different types of cancer (lung, breast, stomach,
liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic,
thyroid, malignant lymphoma, pancreatic) although the sample size
for 9 of the cancers was not statistically significant. Clinical
trials of DR-70(R) have been conducted in Canada, China, Germany,
Taiwan and Turkey. DR-70(R) can detect many kinds of cancer using a
single tube of blood, eliminating the need for costly, multiple
tests. AMDL also owns a combination immunogene therapy technology
that is a possible treatment for those already diagnosed with
cancer and could eventually be used as a vaccine to protect
patients known to be at risk because of a family history for
certain types of cancer. The combination therapy both builds the
body's immune system and destroys cancer cells. More information
about AMDL and its additional products can be obtained at
http://www.amdlcorporate.com/. Forward-Looking Statements
Statements in this press release may constitute forward-looking
statements and are subject to numerous risks and uncertainties,
including the failure to complete successfully the development of
new or enhanced products, the Company's future capital needs, the
lack of market demand for any new or enhanced products the Company
may develop, any actions by the Company's partners that may be
adverse to the Company, the success of competitive products, other
economic factors affecting the Company and its markets, and other
risks detailed from time to time in the Company's filings with the
Securities and Exchange Commission. The actual results may differ
materially from those contained in this press release. The Company
disclaims any obligation to update any statements in this press
release. DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President
& CEO of AMDL, Inc., +1-714-505-4460 Web site:
http://www.amdlcorporate.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jul 2023 to Jul 2024